Skip to main content
. 2017 Aug 12;9(8):107. doi: 10.3390/cancers9080107

Figure 1.

Figure 1

Current algorithm proposed at the LPCE (Nice Hospital, France) for ALK testing [incorporating into the standard of care ROS1 status and Epidermal Growth Factor Receptor gene (EGFR) mutation testing in lung adenocarcinoma].